2024-2025 - CIHR - The impact of language on care and outcomes in patients with prostate or breast cancer ($100,000)

2024-2025 - INVENT-VTE - A pilot randomized controlled trial assessing the strategies for Anticoagulation in patients with thrombocytopenia and cancer-associated Thrombosis (START pilot trial) ($20,000)

2024-2027 - TOHAMO- A prospective management cohort study of catheter-related upper extremity deep vein thrombosis in patients with cancer: the STREAM-Line Study ($100,000)

2023-2024 - CIHR- EPIphANy (Evaluation of Pharmacological Interactions with Anticoagulants in caNcer patients) program - prostate cancer cohort ($164,476)

2022-2026 - TOHAMO - START pilot randomized controlled trial (STrategies for Anticoagulation in patients with thRombocytopenia and cancer-associated Thrombosis) ($181,100)

2021- 2023- CIHR - Reducing bleeding with DOACs in breast cancer patients: The STOP-Bleed Cancer Study ($110,000)

2018-2020 - ISTH - An international registry of the safety and efficacy in cancer patients with concurrent use of direct oral anticoagulants and targeted cancer therapies (TacDOAC registry) ($25,900.82)